The European Commission approves AstraZeneca's (AZN) Truqap in combination with Faslodex for ER-positive, HER2-negative advanced or metastatic breast...
Vous n'êtes pas connecté
The CAPItello─290 phase III trial for Truqap (capivasertib) in combination with paclitaxel in patients with locally advanced (inoperable) or metastatic triple─negative breast cancer (TNBC) did not meet the dual primary endpoints of
The European Commission approves AstraZeneca's (AZN) Truqap in combination with Faslodex for ER-positive, HER2-negative advanced or metastatic breast...
Breast cancer is a complex disease with varying degrees of severity and treatment approaches. Central to understanding and managing breast cancer is...
The CHMP recommends approval of AstraZeneca's (AZN) Imfinzi plus Lynparza for treating primary advanced or recurrent endometrial cancer based on data...
The CHMP recommends approval of AstraZeneca's (AZN) Imfinzi plus Lynparza for treating primary advanced or recurrent endometrial cancer based on data...
Bristol Myers (BMY) wins FDA approval for Krazati, in combination with Erbitux, as a targeted treatment option for adult patients with...
PRINCETON, N.J.--(BUSINESS WIRE) June 21, 2024 -- Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA)...
Alnylam (ALNY) soars as its phase III study, seeking to expand Anvuttra's label to include the treatment of ATTR amyloidosis with cardiomyopathy,...
FRIDAY, June 21, 2024 -- The U.S. Food and Drug Administration has approved Keytruda (pembrolizumab) plus chemotherapy as treatment for adult...
The European Medicines Agency accepts GSK's application for the expanded use of Jemperli plus chemotherapy to include all adult patients with primary...
South San Francisco, CA -- July 3, 2024 -- Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the Phase II/III...